Latest Press Releases
Nov 1, 2017 • 4:10pm EDT
Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results
-- Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs -- -- Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for SYN-004 (ribaxamase) -- -- Conference Call Today, November 1, 2017, at 4:30 p.m. EDT -- ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three months ended September 30, 2017. ...